Actively Recruiting
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
Led by Nanjing Leads Biolabs Co.,Ltd · Updated on 2026-05-13
140
Participants Needed
6
Research Sites
113 weeks
Total Duration
On this page
Sponsors
N
Nanjing Leads Biolabs Co.,Ltd
Lead Sponsor
S
Shanghai Zhongshan Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
An open-label, multicenter, phase II clinical study to evaluate the efficacy and safety of LBL-024 in combination with other drugs for the treatment of patients with advanced solid tumour.
CONDITIONS
Official Title
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 75 years at the time of signing informed consent
- Agree to follow the treatment regimen, visit schedule, laboratory tests, and other protocol requirements
- Eastern Cooperative Oncology Group (ECOG) physical status score of 0 or 1
- Expected survival time of at least 12 weeks
- At least one measurable lesion based on RECIST 1.1 criteria
- Adequate organ and bone marrow function as shown by lab tests
- Males with fertility and females of childbearing age willing to use effective contraception from consent signing to 6 months after last drug dose
You will not qualify if you...
- Participation in other antineoplastic clinical trials within 4 weeks prior to first study drug use
- Expected to receive other systemic or local anti-tumor therapy outside this study during the trial
- Use of immunomodulatory drugs within 2 weeks prior to first study drug use
- Active infection requiring intravenous anti-infective therapy within 2 weeks before first dose
- Clinically uncontrollable pleural effusion, pericardial effusion, ascites, or needing repeated drainage or intervention
- History of immunodeficiency including HIV positive status
- Women who are pregnant or breastfeeding
- History of mental illness affecting understanding or consent, drug abuse, alcoholism, or addiction
- Other conditions deemed by the investigator to affect compliance or suitability for the study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Henan Cancer Hospital
Zhengzhou, Henan, China, 450008
Actively Recruiting
2
Xiangyang Central Hospital
Xiangyang, Hubei, China, 441106
Actively Recruiting
3
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China, 330029
Actively Recruiting
4
Zhongshan Hospital of Fudan University
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
5
Sir Run Run Shaw Hospital (SRRSH) Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310016
Actively Recruiting
6
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310022
Actively Recruiting
Research Team
J
Jian zhou
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here